FUSILEV regnskabsåret 2010 salg op med 156% vs. regnskabsåret 2009
Zevalin salg op med 54% og 84% vs. fjerde kvartal og regnskabsåret 2009.
2011/2012 Corporate Events and Potential Valuation Catalysts.
FUSILEV®..
FDA PDUFA Action date in metastatic colorectal cancer by April 29, 2011.
ZEVALIN®..
Anticipate FDA decision on bioscan removal before the end of 2011;
Initiation of a Diffuse Large B-Cell Lymphoma trial in 2011.
Belinostat..
Complete enrollment in registrational study and file rolling NDA for Peripheral T-Cell Lymphoma in 2011/2012.
Apaziquone..
Anticipate filing NDA for bladder cancer in 2012.
Real Time 7.44 +0.54 (7.83%)
Zevalin salg op med 54% og 84% vs. fjerde kvartal og regnskabsåret 2009.
2011/2012 Corporate Events and Potential Valuation Catalysts.
FUSILEV®..
FDA PDUFA Action date in metastatic colorectal cancer by April 29, 2011.
ZEVALIN®..
Anticipate FDA decision on bioscan removal before the end of 2011;
Initiation of a Diffuse Large B-Cell Lymphoma trial in 2011.
Belinostat..
Complete enrollment in registrational study and file rolling NDA for Peripheral T-Cell Lymphoma in 2011/2012.
Apaziquone..
Anticipate filing NDA for bladder cancer in 2012.
Real Time 7.44 +0.54 (7.83%)